Showing 2571-2580 of 7591 results for "".
- Upadacitinib Effective in Adolescents With AD Through 76 Weekshttps://practicaldermatology.com/news/upadacitinib-effective-adolescents-ad-through-76-weeks/2468724/Long-term treatment of adolescents with moderate-to-severe atopic dermatitis (AD) with upadacitinib demonstrated a favorable benefit-risk profile, with sustained efficacy responses through 76 weeks, in a study published in JAMA Dermatology. “Upadacitinib in Adolescents With Moderate to Sev
- Almirall Announces Scientific Research Hub at R&D Centerhttps://practicaldermatology.com/news/almirall-announces-scientific-research-hub-rd-center/2468710/Almirall announced the launch of “The Hive,” a novel scientific research hub located at its R&D center in Barcelona, Spain. According to a press release, the Hive is designed to foster collaboration among researchers from biotech companies, start-ups, academia, and Almirall’s
- J&J Seeks FDA Approval for Pediatric Tremfya Indicationshttps://practicaldermatology.com/news/jj-seeks-fda-approval-pediatric-tremfya-indications/2468706/Johnson & Johnson (J&J) has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Tremfya (guselkumab), seeking approval for pediatric indications. Tremfya, the first approved monoclonal antibody IL-23 inhibitor that select
- Early-Onset AD Linked to Higher Rates of Atopic Marchhttps://practicaldermatology.com/news/early-onset-ad-linked-higher-rates-atopic-march/2468704/Early-onset atopic dermatitis (AD) is associated with higher rates of developing atopic march conditions compared to controls, according to new research in the Journal of the American Academy of Dermatology. “Particular attention should be paid towards risk factors and atopic marc
- Analysis: Dermoscopy Raises Diagnostic Odds for Melanoma Accuracyhttps://practicaldermatology.com/news/analysis-dermoscopy-raises-diagnostic-odds-melanoma-accuracy/2468666/Experienced dermatologists achieve significantly higher diagnostic accuracy for skin cancer than primary care physicians (PCPs), particularly when using dermoscopy, according to a new meta-analysis of 100 studies. The review, published in JAMA Dermatology, focused on diagnostic accuracy fo
- Study Links Skin Microbiota and AD Alleviation via Melatoninhttps://practicaldermatology.com/news/study-links-skin-microbiota-and-ad-alleviation-melatonin/2468664/A new study published in the Journal of Allergy and Clinical Immunology indicates melatonin has been shown to reduce atopic dermatitis (AD) symptoms by altering skin microbiota composition, with short-chain fatty acids (SCFAs) such as propionic acid playing a key role in this process. Alth
- Dupilumab Shows Long-Term Survival Rates in Treating Moderate-to-Severe Atopic Dermatitishttps://practicaldermatology.com/news/dupilumab-shows-long-term-survival-rates-treating-moderate-severe-atopic-dermatitis/2468646/A recent literature review of published studies suggested that dupilumab maintained survival rates of 80–90% at 1, 2, and 3 years, significantly exceeding the 20-41% rates observed for cyclosporine and methotrexate during comparable periods. "The aim of this literature review is to describ
- Acne Insights: Strategies and Solutions at 2024 SDPA Fallhttps://practicaldermatology.com/news/acne-insights-strategies-and-solutions-2024-sdpa-fall/2468634/The SDPA’s 22nd Annual Fall Dermatology Conference was held last week at the Fontainebleau in Las Vegas. Conference Medical Director Hilary Baldwin, MD, joined Shanna Miranti, MPAS, PA-C, in a discussion called “Acne Insights: Expert Strategies and Solutions from the Pros.” The presentatio
- Analyses: Ruxolitinib Cream Reduces AD Symptom Burden in 12 Hourshttps://practicaldermatology.com/news/analyses-ruxolitinib-cream-reduces-ad-symptom-burden-12-hours/2468615/Ruxolitinib cream significantly reduced skin pain and improved patient-reported outcomes (PROs) in individuals with mild-to-moderate atopic dermatitis (AD), with improvements sustained over 52 weeks, according to data from the TRuE-AD1 and TRuE-AD2 studies. Researchers the results publishi
- Botanix Announces Expanded Payer Coverage for Sofdrahttps://practicaldermatology.com/news/botanix-announces-expanded-payer-coverage-sofdra/2468602/Botanix announced today that Ascent Health, second largest Payer (insurer) organization in the US, will now cover Sofdra™ (sofpironium) topical gel, 12.45%, for the treatment of primary axillary hyperhydrosis. According to a press release from Botanix, Ascent represents approximat